Target Validation Information
TTD ID	T27137
Target Name	Metabotropic glutamate receptor 1 (mGluR1)
Type of Target	Discontinued
Drug Potency against Target	PF-1913539	Drug Info	Ki = 0.6 nM	[10]
		Drug Info	Ki = 250 nM	[2]
	(3,4-dimethylphenyl)(4-phenoxyphenyl)methanone	Drug Info	IC50 = 15300 nM	[6]
	(E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone	Drug Info	Ki = 21 nM	[6]
	(E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one	Drug Info	Ki = 5230 nM	[6]
	2-methyl-6-(phenylethynyl)pyridine	Drug Info	Ki = 36 nM	[8]
	4-(cyclohexyloxy)quinazoline	Drug Info	Ki = 694 nM	[5]
	6-bromo-N-(3-chlorophenyl)quinazolin-4-amine	Drug Info	IC50 = 398 nM	[7]
	N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine	Drug Info	Ki = 1650 nM	[5]
	N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine	Drug Info	Ki = 34 nM	[5]
	N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide	Drug Info	Ki = 6550 nM	[1]
	N-(2-phenylpropyl)quinoxaline-2-carboxamide	Drug Info	Ki = 22 nM	[1]
	N-(3-bromophenyl)-6-chloroquinazolin-4-amine	Drug Info	IC50 = 955 nM	[7]
	N-(3-bromophenyl)-6-fluoroquinazolin-4-amine	Drug Info	IC50 = 713 nM	[7]
	N-cyclohexylquinazolin-4-amine	Drug Info	Ki = 27 nM	[5]
	N-cyclohexylquinolin-4-amine	Drug Info	Ki = 6160 nM	[5]
	N-phenethylquinoxaline-2-carboxamide	Drug Info	Ki = 69 nM	[1]
	NPS-2390	Drug Info	IC50 = 5 nM	[3]
	Pyrazine-2-carboxylic acid adamantan-1-ylamide	Drug Info	IC50 = 7000 nM	[3]
	Quinoline-2-carboxylic acid adamantan-1-ylamide	Drug Info	IC50 = 440 nM	[3]
	Quinoline-3-carboxylic acid adamantan-1-ylamide	Drug Info	IC50 = 52 nM	[3]
	VU0080241	Drug Info	IC50 = 2600 nM	[4]
	[3H]quisqualate	Drug Info	IC50 = 25 nM	[9]
Action against Disease Model	AZD-9272	Drug Info	AZD 9272, a metabotropic glutamate receptor (mGLUR) antagonist, had IC50 values ranging from 0.02 to 2 mcM in vivo.
References
REF 1	Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90.
REF 2	Synthesis, molecular modeling studies, and preliminary pharmacological characterization of all possible 2-(2'-sulfonocyclopropyl)glycine stereoisom... J Med Chem. 2007 Sep 20;50(19):4630-41.
REF 3	Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47.
REF 4	Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel ... Bioorg Med Chem Lett. 2008 Oct 15;18(20):5626-30.
REF 5	In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4.
REF 6	Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15.
REF 7	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
REF 8	Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4371-5.
REF 9	Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9.
REF 10	Pharmacology of adenosine A2A receptors and therapeutic applications. Curr Top Med Chem. 2003;3(4):413-26.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.